3-[3-Cyclopentyl-1-oxopropyl]-4-(phenylmethyl)-2-oxazolidinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-[3-Cyclopentyl-1-oxopropyl]-4-(phenylmethyl)-2-oxazolidinone
• 英文别名: 4-benzyl-3-(3-cyclopentylpropanoyl)-1,3-oxazolidin-2-one
• 化学式: C₁₈H₂₃NO₃
• 分子量: 301.4
• InChiKey: WWXZRKUEKAWUDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  溴乙酸叔丁酯 、 3-[3-Cyclopentyl-1-oxopropyl]-4-(phenylmethyl)-2-oxazolidinone 在 溴乙酸叔丁酯 作用下， 以76的产率得到tert-butyl (3R)-4-[(4S)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-3-(cyclopentylmethyl)-4-oxobutanoate
  参考文献：
  名称：

  Process for the preparation of hydroxamic acid derivatives

  摘要：

  本发明提供了一种改进的制备羧酸的羟基氨基甲酰衍生物的方法，使用羧酸的羟胺盐作为试剂。

  公开号：

  US06452010B1
• 作为产物：
  描述：

  3-环戊基丙酰氯 、 (S)-4-苄基-2-唑烷酮 生成 3-[3-Cyclopentyl-1-oxopropyl]-4-(phenylmethyl)-2-oxazolidinone
  参考文献：
  名称：

  Process for the preparation of hydroxamic acid derivatives

  摘要：

  本发明提供了一种改进的制备羧酸的羟基氨基甲酰衍生物的方法，使用羧酸的羟胺盐作为试剂。

  公开号：

  US06452010B1

文献信息

• Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production
  申请人：——

  公开号：US20020052360A1

  公开（公告）日：2002-05-02

  This invention relates to novel lactams having the formula (I): 1 to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式(I)的新颖内酰胺：1及其药物组合物及其使用方法。这些新颖化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ-肽的产生，从而防止神经系统中淀粉样蛋白沉积的形成。更具体地，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，如阿尔茨海默病和唐氏综合症。
• Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production
  申请人：——

  公开号：US20030166636A1

  公开（公告）日：2003-09-04

  This invention relates to novel lactams having the formula (I): 1 to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式(I)的新颖内酰胺：及其药物组合物及其使用方法。这些新颖化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ-肽的产生，从而防止神经性淀粉样蛋白沉积的形成。更具体地说，本发明涉及治疗与β-淀粉样蛋白产生相关的神经障碍，如阿尔茨海默病和唐氏综合症。
• [EN] NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS, LEURS COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES D'UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：EUROSCREEN SA

  公开号：WO2011151434A1

  公开（公告）日：2011-12-08

  The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.

  本发明涉及公式（I）的新化合物及其在治疗代谢性疾病中的应用。
• Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production
  申请人：Olson E. Richard

  公开号：US20050113363A1

  公开（公告）日：2005-05-26

  This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式(I)的新型内酰胺，它们的制药组合物以及它们的使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地抑制Aβ肽的产生，从而防止神经淀粉样蛋白沉积物的形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，例如阿尔茨海默病和唐氏综合症。
• CCK analogs with appetite regulating activity
  申请人：Hoffman-La Roche Inc.

  公开号：US05128448A1

  公开（公告）日：1992-07-07

  The invention is directed to novel CCK analogs wherein Tryptophan and/or Phenylalamine are substituted with a radical which provides enhanced appetite suppressant activity to the peptide.

  本发明涉及新型CCK类似物，其中色氨酸和/或苯丙氨酸被取代为提供肽的增强食欲抑制活性的基团。